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ABSTRACT: The Parkinson’s disease-associated protein
α-synuclein exhibits signiﬁcant conformational heteroge-
neity. Bacterially expressed α-synuclein is known to bind
to copper, resulting in the formation of aggregation-prone
compact conformations. However, in vivo, α-synuclein
undergoes acetylation at its N-terminus. Here the eﬀect of
this modiﬁcation and the pathological H50Q mutation on
copper binding and subsequent conformational transitions
were investigated by electrospray ionization−ion mobility
spectrometry−mass spectrometry. We demonstrate that
acetylation perturbs the ability of α-synuclein to bind
copper and that the H50Q missense mutation in the
presence of N-terminal acetylation prevents copper
binding. These modiﬁcations and mutations prevent the
formation of the most compact conformations and inhibit
copper-induced aggregation.
α-Synuclein (α-syn) is a highly conserved presynaptic protein
associated with Parkinson’s disease (PD) and other neuro-
degenerative disorders.1 Despite α-syn being one of the most
abundant proteins in the brain, its precise function is poorly
understood, although it is known to play a role in maintaining
synaptic integrity and function.2 Fibrillar aggregates of α-syn are
the primary constituents of Lewy bodies, intracytoplasmic
inclusions that are a pathological hallmark of PD.3 This highly
ordered, ﬁbrillar form of α-syn is in contrast to the usual
disordered monomeric form of the protein.4 It is known that α-
syn can exhibit signiﬁcant conformational heterogeneity,5 with
collapsed conformers of α-syn linked to its aggregation.6 Certain
environmental conditions are capable of inducing such
conformations, including the presence of various divalent metal
ions, including Cu2+.7
Epidemiological studies imply that a high level of exposure to
metals can act as a potential risk factor in certain nonfamilial
forms of PD,12 and alterations in metal homeostasis have been
associated with many neurodegenerative diseases, including
PD.13 Increased levels of iron in the substantia nigra of PD
patients are well documented,14 with some studies ﬁnding an
increase in the Fe3+/Fe2+ ratios of patients.15,16 Abnormal
distributions of copper in PD patients have also been observed.17
The maintenance of metal homeostasis is vital for health as
various metals play essential roles as cofactors in many biological
processes. For example, the enzyme tyrosine hydroxylase,
responsible for catalyzing the ﬁrst step in the conversion of
tyrosine to dopamine, requires ferrous iron to do so.8 A possible
role for α-syn in iron homeostasis has been suggested because of
a putative iron response element identiﬁed in the 5′-untranslated
region of α-syn mRNA.9 Iron response elements are a
mechanism of post-transcriptional control of gene expression,
commonly found in proteins involved in iron homeostasis, such
as transferrin receptor protein 1 and ferritin.10 It has also been
proposed that α-syn may have ferrireductase activity, reducing
Fe3+ to Fe2+, requiring copper bound to the protein to cycle
between its oxidized and reduced forms, and hence binds these
metals.11
Polyvalent metals such as Cu2+ are known to enhance α-syn
aggregation, leading to increased rates of ﬁbril formation in vitro.6
Mapping studies employing circular dichroism, calorimetric
titrations, nuclear magnetic resonance, and electron para-
magnetic resonance spectroscopy have demonstrated the
population of a collapsed species of α-syn in the presence of
this metal.18−20,41 While most metal−α-syn interactions are
nonspeciﬁc or low-aﬃnity, this protein has a high binding aﬃnity
for Cu2+. Evidence suggests α-syn is capable of binding Cu2+ at
three speciﬁc sites:21 a high-aﬃnity N-terminal site where Cu2+ is
anchored by the freely available amino-terminal nitrogen, a
lower-aﬃnity site anchored by the imidazole ring of the histidine
at position 50, and a low-aﬃnity site at the C-terminus of the
protein. Therefore, a paradoxical situation exists between the
ability of α-syn to undergometal-induced aggregation in vitro and
its potential role as a metal binding protein in vivo.
In addition to α-syn being the main constituent of Lewy
bodies, genetic evidence also points to the involvement of the
protein in PD. Multiplications and mutations of SNCA, the gene
encoding α-syn, have been shown to cause familial forms of PD.
Most recently identiﬁed has been the H50Q missense mutation
in SNCA exon 4, reported by two research groups in 2013.22,23
This mutation has been shown to accelerate ﬁbril formation of
the protein,24 reduce its solubility,25 and increase its level of
secretion and toxicity in cell culture.26 This mutant is of interest
in relation to copper binding as the loss of the histidine imidazole
ring would presumably aﬀect α-syn’s copper binding ability.
However, studies investigating copper binding of α-syn in vitro
where the H50 residue has been mutated have found negligible
eﬀects on copper binding; this is contrary to what would be
predicted by the removal of a copper-anchoring site.27 The eﬀect
of the H50Q familial mutation on copper binding was
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investigated by Proukakis et al., who found the mutant was able
to bind to copper, but in a manner diﬀerent from that of the wild-
type (WT) protein, with binding only involving the high-aﬃnity
N-terminal site. These results about the role of H50 (refs 23−27)
were gained using unmodiﬁed α-syn, which lacks N-terminal
acetylation. This leaves the question of how this physiologically
relevant N-terminal modiﬁcation aﬀects metal binding and
aggregation of this mutant.
In vivo α-syn is known to be constitutively acetylated at its N-
terminus, a common modiﬁcation of cytosolic proteins,
particularly those that retain their initiating methionine
residue.28 α-Syn was ﬁrst identiﬁed as being acetylated when it
was puriﬁed from Lewy bodies using liquid chromatography and
tandem mass spectroscopy,29 which has since been conﬁrmed in
α-syn isolated from brain tissue homogenate30 and erythro-
cytes.31 In recent years, a number of in vitro studies have aimed to
elucidate the eﬀect of acetylation on α-syn. Such studies have
shown that acetylation results in an increase in the lipid binding
aﬃnity of α-syn,32 alters its transient secondary structure,33 and
decreases aggregation rates.34N-Terminal acetylation of α-syn is
an important modiﬁcation in relation to its Cu2+ binding as the
transfer of an acetyl group to the copper-anchoring amino-
terminal nitrogen has the potential to alter the protein’s Cu2+
binding ability. It has recently been demonstrated that N-
terminally acetylated α-syn lacks its high-aﬃnity N-terminal Cu2+
binding site and undergoes altered ﬁbril formation in the
presence of this metal.35
To date, the eﬀect of the familial H50Q mutation on Cu2+
binding of biologically relevant N-terminally acetylated α-syn has
not been investigated. Prior studies of the WT N-terminally
acetylated form have successfully used ensemble-based spectros-
copy techniques to probe structural changes caused by metal
binding.35 However, the changes to the individual conforma-
tional states of α-syn have not been investigated. In this study,
electrospray ionization−ion mobility spectrometry−mass spec-
trometry (ESI−IMS−MS) has been used to observe the copper
binding and subsequent conformational transitions of individual
conformational states of unmodiﬁed and acetylated wild-type
and H50Q α-syn, using conditions suitable to maintain protein−
metal complexes in the gas phase. ESI−IMS−MS has been
utilized because of its ability to interrogate dynamic ensembles of
the same mass by separating extended and collapsed
conformations.36Changes in solution conformation are detected
in the gas phase as changes in collisional cross-sectional area
(CCS). This method also allows the binding of ligands to speciﬁc
conformational states to be determined.37
To address the Cu2+ binding properties of N-terminally
acetylated α-syn, modiﬁed protein was produced through co-
expression of the α-syn plasmid with the pNatB plasmid.38
Although α-syn is described as a predominantly natively
unstructured protein, it is comprised of a range of co-populated
conformational families under equilibrium, which have been
investigated using ESI−IMS−MS by various groups.39−42 Here,
both extended and compact conformational states were observed
for unmodiﬁed and acetylated WT and H50Q α-syn, equivalent
to those previously reported.43 Figure S1 shows the Driftscope
plot and overlaid mass spectrum of each of the four proteins.
Individual CCS values were determined for each charge state ion
by ﬁtting the arrival time distributions (ATDs) to the minimal
number of Gaussian distributions, as shown in Figure S2a. The
center CCS of each of these individual distributions was plotted
against charge state, shown in Figure S2b. Conformational
families, with multiple populations of both extended and
compact conformations, can be observed. A primarily extended
population is seen in charge state ions +8 to +15, while a
subpopulation of more compact conformations is seen
predominantly at charge state ions +6 to +9, with multiple
overlapping features in both series. An increase in CCS is seen
through the extended series, presumably as a result of Coulombic
repulsion between charges, resulting in more open structures.
Compared to that of unmodiﬁed WT α-syn, neither N-
acetylation nor H50Q mutation of the protein resulted in
signiﬁcant changes in observed CCSs or observable changes in
the relative populations of the extended and compact
conformations, demonstrating that the unbound metal free
conformational states of these proteins are comparable.
To determine the degree of binding of Cu2+ to α-syn, mass
spectra were recorded at a 1:1 protein:metal ratio immediately
upon the addition of CuCl2. Figure 1 shows resulting spectra for
the +7 charge state ion of unmodiﬁed and acetylated WT and
H5OQ α-syn in apo and holo forms. While the +7 charge state
ion has been highlighted here to illustrate Cu2+ binding, the same
pattern of Cu2+ binding was seen across all charge states of the
protein, with binding to each individual charge state ion shown in
Figure S3.
All charge states of unmodiﬁed α-syn were able to bind one or
two Cu2+ ions, indicating copper binding sites are available in all
monomer conformations present under these conditions. This
demonstrates, in agreement with α-syn−peptide binding
studies,44 that initial Cu2+ binding is determined at the primary
structural level, as the extended, disordered state is capable of
binding Cu2+ ions without a pronounced conformational change.
At the concentration of copper tested here, the entire population
of unmodiﬁed α-syn was found in its holo form, demonstrating a
high aﬃnity for this metal. In contrast to the case for the
unmodiﬁed protein, in the presence of equimolar Cu2+ the
Figure 1. Binding of Cu2+ to unmodiﬁed and acetylated WT and H50Q
α-syn at the +7 charge state ion. Spectra acquired at a protein
concentration of 10 μMwith CuCl2 ratios of 1:0 (red) and 1:1 (green).
Unbound forms of α-syn marked with an empty circles, the number of
bound Cu2+ ions marked with ﬁlled circles. The x axis represents m/z,
and the y axis represents relative abundance.
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majority of acetylated α-syn remains in its apo form, with smaller
amounts binding either one or two copper ions. These results, in
agreement with previous studies,35 indicate that acetylation
weakens the ability of α-syn to bind Cu2+, presumably as a result
of the N-terminal binding site becoming unavailable upon
acetylation. In agreement with others, we found that the
unmodiﬁed H50Q mutation does not appear to hinder copper
binding, indicating that the H50 residue does not play a
prominent role in the binding of copper to the unmodiﬁed
protein. However, the previously unstudied acetylated H50Q
mutant shows greatly impaired copper binding, with only a small
proportion binding to one Cu2+ ion, indicating that the histidine
at position 50 plays a key role in the binding of copper to
acetylated α-syn.
Compact conformations of α-syn are known to be
aggregation-prone, and the equilibrium of conformations can
be shifted toward the compact states under certain conditions.
Polyvalent metal ions have the propensity to shift the
conformational equilibrium and trigger structural rearrange-
ments. Ion mobility spectra were acquired to investigate changes
in α-syn conformations that occur upon Cu2+ binding. CCSs
were calculated for each charge state of unmodiﬁed and
acetylated WT and H50Q α-syn, in the presence and absence
of Cu2+, with the results for the +7 charge state ion shown in
Figure 2 (taken as being representative of the compact
conformations). Figure S5 details the ATD of all charge states
of the four proteins in the absence or presence of equimolar
copper. Gaussian ﬁtting was performed on each of the ATDs, and
the areas under each curve were used to gain estimates of the
population of each conformational state. The ATDs of the +7
charge state ion of all four unbound proteins have three distinct
conformational distributions, populated to similar extents, with a
most compact distribution centered at a CCS of 1608 Å2, an
intermediate conformation centered at a CCS of 1840 Å2, and an
extended state centered at a CCS of 2079 Å2.
When unmodiﬁed α-syn is bound to one Cu2+ ion, an overall
shift toward the more compact conformations can be observed
(from 26 to 47% of the +7 charge state ion) with a concurrent
reduction in the proportions of the most extended and
intermediate states. Binding of a second Cu2+ ion results in a
further increase in the proportion of compact conformations to
54%. Similar shifts to the more compact states are observed
across the +8 to +12 charge state ions as shown in Figure S5.
When Cu2+ binds to the unmodiﬁed H50Q mutant, the same
pattern of conformational change occurs, indicating that H50 is
not directly involved in copper binding in the unmodiﬁed
proteins. When Cu2+ binds to the acetylated proteins, the shift to
the more compact conformations is not observed. In contrast to
the unmodiﬁed proteins, a larger proportion of the +7 charge
state ion remains in the more extended states, demonstrating that
acetylated α-syn undergoes reduced conformational changes
upon Cu2+ binding.
The aggregation propensity of each of the proteins in the
presence and absence of Cu2+ was investigated using thioﬂavin T
ﬂuorescence. The lag time was determined by calculating the
intercept between the maximal derivative and the pretransitional
baseline. Figure 3 shows the mean and standard deviation
aggregation lag time of ﬁve repeats; raw data are shown in Figure
S6. In agreement with others, we have found that Cu2+ decreases
the aggregation lag time of unmodiﬁed α-syn and that acetylation
hinders this eﬀect. The H50Q mutant displays an aggregation
propensity higher than that of the WT protein, with a further
reduction in lag time in the presence of Cu2+. The previously
unstudied acetylated H50Q mutant shows the same increased
aggregation propensity as the unmodiﬁed mutant, but in this
case, no further decrease in lag time is observed upon the
addition of Cu2+, consistent with the impaired Cu2+ binding and
lack of conformational change seen with this protein by ESI−
IMS−MS.
In summary, it has been demonstrated that binding of Cu2+ to
unmodiﬁed α-syn can induce a conformational change to a more
compact state41 which is prone to aggregation,6 potentially
playing a role in the pathogenesis of PD. Results presented here
demonstrate that the biologically relevant, acetylated α-syn
undergoes altered conformational changes upon Cu2+ binding
compared to the better studied unmodiﬁed protein, with an
observable decrease in the binding aﬃnity for Cu2+. It is an
important observation that α-syn is N-terminally acetylated29 in
vivo, and the eﬀect of this modiﬁcation needs to be considered
Figure 2. Arrival time distributions and experimental collisional cross
sections of the +7 charge state ion of unmodiﬁed and acetylatedWT and
H50Q α-syn. Apo and Cu2+-bound forms resulting from mixing 10 μM
α-syn with equimolar CuCl2. The percentages of alternate populations
of diﬀering CCSs were calculated using Gaussian ﬁtting, indicated by the
green, purple, and black curves.
Figure 3. Copper-induced aggregation of α-syn as monitored by
thioﬂavin T. α-Syn was incubated at 70 μM alone (black) or in the
presence of equimolar CuCl2 (blue). Statistical signiﬁcance determined
by the Kruskall−Wallis with Conover−Inman post hoc analysis test (P
≤ 0.05).
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when investigating binding of metal to this protein. Acetylation in
vitro perturbs the ability of α-syn to bind Cu2+ and attenuates the
metal-induced formation of the most compact conformations. In
agreement with others,35 we have shown that Cu2+ has a
weakened eﬀect on the aggregation kinetics of acetylated α-syn,
which can be explained by the reduced shift toward the
aggregation-prone, compact state as observed by ESI−IMS−
MS. As α-syn is acetylated in vivo, if Cu2+ is indeed involved in the
pathogenesis of PD via interactions with α-syn, it may occur
through mechanisms other than the formation of an aggregation-
prone conformation.
Results presented here are the ﬁrst, to the best of our
knowledge, describing the eﬀect of acetylated on H50Q α-syn
copper binding. We have demonstrated that while the H50Q
mutation does not appear to alter the Cu2+ binding of
unmodiﬁed α-syn, the acetylated H50Q mutant has greatly
impaired Cu2+ binding. This demonstrates the importance of the
N-terminus and the role of H50 in the Cu2+ binding site of α-syn
and suggests that the proposed C-terminal binding region has
little inﬂuence. If Cu2+ binding is important for α-syn’s
physiological function, such as its suggested role as a
ferrireductase, then the familial H50Q mutation may result in
loss of function due to the protein not being able to bind Cu2+ in
the usual fashion. These results highlight the need to take into
account post-translational modiﬁcations when investigating the
metal binding propensity of α-syn and its mutants.
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